Treatment of Multiresistant Prolactinomas with a Combination of Cabergoline and Octreotide LAR

Overview

Journal Endocrine

Specialty Endocrinology

Date 2018 Jun 28

PMID 29948930

Citations 23

Authors

Ernesto Sosa-Eroza

Etual Espinosa

Claudia Ramirez-Renteria

Victoria Mendoza

Rocio Arreola

Moises Mercado

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Dopamine agonist (DA)-resistant prolactinomas are rare but they constitute a real challenge, since there are few therapeutic alternatives left for these patients.

Design And Setting: Proof-of-concept study at a tertiary care, referral center.

Patients And Methods: The studied population consisted of five patients (one female and four males, mean age at diagnosis 23.5 ± 19) with macroprolactinomas with persistent hyperprolactinemia and/or tumor mass despite high doses of cabergoline (CBG) and pituitary surgery, to whom 20 mg monthly of octreotide LAR was added for 6-13 months. Response was evaluated by measuring prolactin (PRL) levels and by magnetic resonance imaging. Immunohistochemistry (IHC) for pituitary hormones, Ki-67, and somatostatin receptor subtypes 2 and 5 was (SSTR2 and 5) was available in two of the subjects.

Results: The addition of octreotide LAR to ongoing CBG treatment had no effect on either PRL levels or tumor size in three patients. In two of the five patients, combination treatment resulted in a significant reduction in PRL concentrations (from 7643 to 200 ng/mL and from 2587 to 470 ng/mL) as well as in adenoma size (93% reduction). IHC evaluation of tumor samples from two patients (a responder and a non-responder) revealed positive immunostaining for PRL and SSTR5 but not for other pituitary hormones or for SSTR2.

Conclusions: The addition of a somatostatin analog to ongoing CBG treatment may be effective in some patients with DA-resistant macroprolactinomas, independently of the adenoma's SSTR expression profile.

Citing Articles

Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas.

Andereggen L, Christ E J Neurooncol. 2025; .

PMID: 39904877 DOI: 10.1007/s11060-025-04958-6.

Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.

Yogeeta F, Rauf S, Devi M, Imran K, Ahmed R, Aruwani P Ann Med Surg (Lond). 2024; 86(8):4613-4623.

PMID: 39118737 PMC: 11305738. DOI: 10.1097/MS9.0000000000002308.

Metastatic pituitary neuroendocrine neoplasms: A case report of a malignant prolactinoma.

Manique I, Amaral S, Rego T, Coelho A, Ponte A, Brito M Clin Case Rep. 2024; 12(4):e8595.

PMID: 38645600 PMC: 11031745. DOI: 10.1002/ccr3.8595.

Current and Perspective Approaches to the Treatment of Prolactinomas.

Tykhonova T, Barabash N, Kanishcheva O Acta Med Litu. 2024; 30(2):96-107.

PMID: 38516518 PMC: 10952428. DOI: 10.15388/Amed.2023.30.2.1.

Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.

Iglesias P J Clin Med. 2024; 13(1).

PMID: 38202123 PMC: 10779494. DOI: 10.3390/jcm13010116.

References

Grottoli S, Gasco V, Broglio F, Baldelli R, Ragazzoni F, Gallenca F . Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma. J Clin Endocrinol Metab. 2006; 91(4):1595-9. DOI: 10.1210/jc.2005-1837. View

Bevan J, Webster J, BURKE C, Scanlon M . Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992; 13(2):220-40. DOI: 10.1210/edrv-13-2-220. View

Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H . Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab. 1999; 84(9):3268-76. DOI: 10.1210/jcem.84.9.5962. View

Webster J, Piscitelli G, Polli A, DALBERTON A, Falsetti L, Ferrari C . The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf). 1993; 39(3):323-9. DOI: 10.1111/j.1365-2265.1993.tb02372.x. View

Shimon I, Sosa E, Mendoza V, Greenman Y, Tirosh A, Espinosa E . Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary. 2016; 19(4):429-36. DOI: 10.1007/s11102-016-0723-4. View

Colao A, Di Sarno A, Pivonello R, Di Somma C, Lombardi G . Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs. 2002; 11(6):787-800. DOI: 10.1517/13543784.11.6.787. View

Gatto F, Feelders R, van der Pas R, Kros J, Waaijers M, Sprij-Mooij D . Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2012; 98(1):E66-71. DOI: 10.1210/jc.2012-2609. View

Fusco A, Lugli F, Sacco E, Tilaro L, Bianchi A, Angelini F . Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary. 2009; 14(4):351-7. DOI: 10.1007/s11102-008-0162-y. View

Liuzzi A, Dallabonzana D, Oppizzi G, Verde G, Cozzi R, Chiodini P . Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med. 1985; 313(11):656-9. DOI: 10.1056/NEJM198509123131103. View

10.

Molitch M . Pharmacologic resistance in prolactinoma patients. Pituitary. 2006; 8(1):43-52. DOI: 10.1007/s11102-005-5085-2. View

11.

Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti A, Culler M . Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol. 2008; 158(5):595-603. DOI: 10.1530/EJE-07-0806. View

12.

Raverot G, Sturm N, De Fraipont F, Muller M, Salenave S, Caron P . Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010; 95(10):4592-9. DOI: 10.1210/jc.2010-0644. View

13.

Gonzalez B, Vargas G, Ramirez C, Asa S, Cheng S, Sandoval C . Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide. Endocrinol Nutr. 2014; 61(10):523-30. DOI: 10.1016/j.endonu.2014.05.006. View

14.

LANDOLT A, Lomax N . Gamma knife radiosurgery for prolactinomas. J Neurosurg. 2001; 93 Suppl 3:14-8. DOI: 10.3171/jns.2000.93.supplement. View

15.

Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D . Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 1994; 60(3):314-22. DOI: 10.1159/000126764. View

16.

Vroonen L, Jaffrain-Rea M, Petrossians P, Tamagno G, Chanson P, Vilar L . Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012; 167(5):651-62. DOI: 10.1530/EJE-12-0236. View

17.

Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M . Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol. 2006; 59(3):274-9. PMC: 1860351. DOI: 10.1136/jcp.2005.026914. View

18.

Mercado M, Espinosa E, Ramirez C . Current status and future directions of pharmacological therapy for acromegaly. Minerva Endocrinol. 2015; 41(3):351-65. View

19.

Espinosa E, Sosa E, Mendoza V, Ramirez C, Melgar V, Mercado M . Giant prolactinomas: are they really different from ordinary macroprolactinomas?. Endocrine. 2015; 52(3):652-9. DOI: 10.1007/s12020-015-0791-7. View

20.

Olukoga A, Kane J . Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf). 1999; 51(1):119-26. DOI: 10.1046/j.1365-2265.1999.00757.x. View